13.09.2022 • NewsWuxinanoparticlesWuXi AppTec

WuXi Opens Lipid Nanoparticle Facility

WuXi STA has opened a sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its campus in Wuxi city, China, in response to rising demand for complex injection dosage forms.

The contract research, development and manufacturing subsidiary of WuXi AppTec said the facility integrates multi-channel chip, micro-mixer and complex preparation systems into a core LNP manufacturing platform that offers significant advantages in drug-loading, liposome particle size control and encapsulation efficiency. 

Its modular design also provides greater processing flexibility, enabling the platform to serve a wide range of manufacturing scales from 10-50 liters per batch, the company noted.

WuXi added that the facility has considerable synergy with the its oligonucleotide CRDMO platform, as the LNP delivery system has particular advantages in overcoming the bioavailability challenge of oligonucleotides and their conjugates. 

New Lipid Nanoparticle (LNP) Production Facility in Wuxi City, China © WuXi...
New Lipid Nanoparticle (LNP) Production Facility in Wuxi City, China © WuXi AppTec

“We will continue to expand our CRDMO platform's capacity and capabilities to enable our partners to accelerate more innovative drugs to market for patients worldwide," said Minzhang Chen, CEO of WuXi STA and co-CEO of WuXi AppTec.

In July, the Shanghai-based firm opened a new continuous manufacturing plant for large-scale API and advanced intermediate production, as well as a large-scale oligonucleotide and peptide manufacturing facility at Changzhou. That same month, WuXi announced plans to invest about $1.43 billion in a new R&D and manufacturing site in Singapore.

Author: Elaine Burridge, Freelance Journalist

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.